Overweight: Clinical Trials

46 trials for Overweight, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

46 terminated. 46 Phase 3, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 346Terminated 46
Phase 25Terminated 5

Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight

Trials (filtered) newest first · largest first

All 46 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
Placebo, ARD-101 - Hyperphagia, Prader-Willi Syndrome
Phase 3TerminatedAardvark Therapeutics, Inc.682024-12-202026-06-30
The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
ARD-101 - Hyperphagia, Prader-Willi Syndrome
Phase 3TerminatedAardvark Therapeutics, Inc.192024-07-232026-06-30
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral Tablet - Endometrial Carcinoma, Obese
Phase 2 / Phase 3TerminatedXiaojun Chen82022-05-012026-06-04
A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome
RAD011, Placebo - Prader-Willi Syndrome
Phase 2 / Phase 3TerminatedRadius Pharmaceuticals, Inc.42022-04-132023-10-19
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution - CKD, Diabetic Kidney Disease
Phase 3TerminatedGeisinger Clinic152021-07-232024-02-09
Balloon to Induce Labor in Generous Women.
Balloon catheter + oral misoprostol, Oral misoprostol alone - Maternal Obesity
Phase 3TerminatedUniversity Hospital, Toulouse4292020-06-262023-05-15
Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients
Lorcaserin 10 mg BID, Matching Placebo BID - Obesity
Phase 3TerminatedKanion & Huawe Medicine Co.,Ltd1002019-09-172022-05-02
Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome
Livoletide, Placebo - Prader-Willi Syndrome, Hyperphagia
Phase 2 / Phase 3TerminatedMillendo Therapeutics SAS1582019-03-252021-02-17
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
Dapagliflozin 10mg, Exenatide 2 mg [Bydureon], Placebo Oral Tablet - Obesity, Diabetes Mellitus, Type 2
Phase 3TerminatedUniversitätsklinikum Hamburg-Eppendorf132018-02-192020-03-31
Preoperative Hexakapron Reduces Bleeding in Bariatric Surgery
tranexamic acid, Placebo - Intra-Operative Injury - Other, Post Operative Hemorrhage
Phase 3TerminatedSheba Medical Center1522017-09-012023-04-19
Randomization of Early Diabetes Screening Among Obese Pregnant Women.
Screening for diabetes with 1-hour GCT and HbA1 - Gestational Diabetes
Phase 3TerminatedUniversity of Illinois at Chicago6002017-03-192020-03-03
Addressing Post Cessation Weight Gain
lorcaserin, Varenicline, Placebo - Obesity, Smoking Cessation
Phase 2 / Phase 3TerminatedMayo Clinic842016-06-152021-06-10
Capsaicin Patches In Knee Osteoarthritis In Obese Patients
capsaicin 8% patches (Qutenza), Placebo patches - Pain
Phase 3TerminatedNadine ATTAL222015-07-012019-04-17
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension - Prader-Willi Syndrome, Obesity
Phase 3TerminatedZafgen, Inc.1082014-09-012017-01-26
Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks
Topiramate, Placebo Comparator - Prader-Willi Syndrome
Phase 3TerminatedAssistance Publique - Hôpitaux de Paris692012-12-012018-04-11
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
PolyGlycopleX® - PGX®, Rice Flour (placebo) - Type II Diabetes Mellitus, Obesity
Phase 3TerminatedInovoBiologic Inc.1002012-10-012021-02-11
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
NB32, PBO, Weight Management Program - Obesity, Overweight
Phase 3TerminatedOrexigen Therapeutics, Inc89102012-06-012017-02-27
Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid
GLP-1 (Liraglutide), Placebo - Obesity
Phase 3TerminatedUniversitätsklinikum Hamburg-Eppendorf22011-12-012022-06-30
Early Versus Delayed Skin Staple Removal Following Cesarean Delivery in the Obese Patient
Removal of surgical skin staples - Wound Complications, Obesity
Phase 2 / Phase 3TerminatedPrisma Health-Upstate2922009-10-012021-03-17
Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients
rimonabant (SR141716) - Obesity, Weight Loss
Phase 3TerminatedSanofi3312008-04-012009-06-17

Showing 20 of 46. Sign in to see all of them.

Narrower conditions

Obesity (38)  ·  Diabetes Mellitus, Type 2 (8)  ·  Prader-Willi Syndrome (8)  ·  Diabetes Mellitus (6)  ·  Hyperphagia (5)  ·  Weight Loss (4)  ·  Dyslipidemias (3)  ·  Body Weight (2)  ·  Cardiovascular Diseases (2)  ·  Obesity, Morbid (2)  ·  Arteriosclerosis (1)  ·  Carotid Artery Diseases (1)  ·  Carotid Stenosis (1)  ·  Diabetes, Gestational (1)

Broader conditions

Nutritional and Metabolic Diseases (46)  ·  Nutrition Disorders (45)  ·  Overnutrition (45)  ·  Pathological Conditions, Signs and Symptoms (45)  ·  Signs and Symptoms (45)  ·  Body Weight (39)  ·  Metabolic Diseases (12)  ·  Glucose Metabolism Disorders (11)  ·  Endocrine System Diseases (10)  ·  Nervous System Diseases (10)  ·  Neurologic Manifestations (9)  ·  Abnormalities, Multiple (8)  ·  Chromosome Disorders (8)  ·  Congenital Abnormalities (8)

Interventions

Rimonabant (11)  ·  N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide (4)  ·  Topiramate (3)  ·  lorcaserin (2)  ·  Anastrozole (1)  ·  BID protein, human (1)  ·  CKD732 (1)  ·  Caloric Restriction (1)  ·  Capsaicin (1)  ·  Diet (1)  ·  Exenatide (1)  ·  Exercise (1)  ·  Flour (1)  ·  Glucagon-Like Peptide 1 (1)  ·  Glycated Hemoglobin (1)

Sponsors

Sanofi (10)  ·  Merck Sharp & Dohme LLC (4)  ·  Pfizer (4)  ·  Aardvark Therapeutics, Inc. (2)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2)  ·  Universitätsklinikum Hamburg-Eppendorf (2)  ·  Abbott (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  C. R. Bard (1)  ·  Children's Heart Center (1)  ·  Geisinger Clinic (1)  ·  InovoBiologic Inc. (1)  ·  Kanion & Huawe Medicine Co.,Ltd (1)  ·  Mayo Clinic (1)  ·  Millendo Therapeutics SAS (1)

Countries

United States (20)  ·  United Kingdom (10)  ·  Canada (9)  ·  France (9)  ·  Australia (8)  ·  Germany (7)  ·  Netherlands (7)  ·  Spain (6)  ·  Finland (5)  ·  Sweden (5)  ·  Czechia (4)  ·  Hungary (4)  ·  Italy (4)  ·  Mexico (4)  ·  South Korea (4)

Top investigators

Jens Aberle, MD (2)  ·  Ahmad O Hammoud, MD (1)  ·  Alex R Chang, MD, MS (1)  ·  Alexandra Kautzky-Willer, Prof. Dr. (1)  ·  Andreas Fritsche, Prof. Dr. (1)  ·  Christophe Vayssiere, Pr (1)  ·  Claire Carette (1)  ·  Deepak L. Bhatt, MD (1)  ·  Dennis Kim, MD (1)  ·  Eric Topol, MD (1)

Results publications

PMID 20157323, PMID 20379151, PMID 20709233, PMID 20965292, PMID 20976246, PMID 21610270, PMID 23567348, PMID 25077901, PMID 26954408, PMID 28556449, PMID 32642971, PMID 36160639, PMID 36996264

NIH funding

2005 (2), K23DA037299 (1)